Anti-inflammatory effects of infliximab and methotrexate on peripheral blood and synovial fluid mononuclear cells: ex vivo study

References

• Verheul MK, Fearon U, Trouw LA, Veale DJ. Biomarkers for rheumatoid and psoriatic arthritis. Clin Immunol 2015;161:2–10.
   PubMed Web of Science ®Google Scholar
• Zabotti A, Salvin S, Quartuccio L, De Vita S. Differentiation between early rheumatoid and early psoriatic arthritis by the ultrasonographic study of the synovio-entheseal complex of the small joints of the hands. Clin Exp Rheumatol 2016;34:459–65.
   PubMed Web of Science ®Google Scholar
• Moreland LW, O’Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial. Arthritis Rheum 2012;64:2824–35.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016;68:1–26.
   PubMed Web of Science ®Google Scholar
• Sedger LM, McDermott MF. TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants - past, present and future. Cytokine Growth Factor Rev 2014;25:453–72.
   PubMed Web of Science ®Google Scholar
• Meier FM, Frerix M, Hermann W, Muller-Ladner U. Current immunotherapy in rheumatoid arthritis. Immunotherapy 2013;5:955–74.
   PubMed Web of Science ®Google Scholar
• Monaco C, Nanchahal J, Taylor P, Feldmann M. Anti-TNF therapy: past, present and future. Int Immunol 2015;27:55–62.
   PubMed Web of Science ®Google Scholar
• Maneiro JR, Salgado E, Gomez-Reino JJ. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions: systematic review and meta-analysis. JAMA Int Med 2013;173:1416–28.
   PubMed Web of Science ®Google Scholar
• Chen SJ, Lin GJ, Chen JW, Wang KC, Tien CH, Hu CF, et al. Immunopathogenic mechanisms and novel immune-modulated therapies in rheumatoid arthritis. Int J Mol Sci 2019;21:20.
   PubMedGoogle Scholar
• Malmstrom V, Catrina AI, Klareskog L. The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. Nat Rev Immunol 2017;17:60–75.
   PubMed Web of Science ®Google Scholar
• Haringman JJ, Gerlag DM, Zwinderman AH, Smeets TJ, Kraan MC, Baeten D, et al. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:834–8.
   PubMed Web of Science ®Google Scholar
• Rana AK, Li Y, Dang Q, Yang F. Monocytes in rheumatoid arthritis: circulating precursors of macrophages and osteoclasts and, their heterogeneity and plasticity role in RA pathogenesis. Int Immunopharmacol 2018;65:348–59.
   PubMed Web of Science ®Google Scholar
• Meroni PL, Valesini G. Tumour necrosis factor alpha antagonists in the treatment of rheumatoid arthritis: an immunological perspective. BioDrugs 2014;28:S5–13.
   PubMed Web of Science ®Google Scholar
• Dulic S, Vasarhelyi Z, Sava F, Berta L, Szalay B, Toldi G, et al. T-cell subsets in rheumatoid arthritis patients on long-term anti-TNF or IL-6 receptor blocker therapy. Mediators Inflamm 2017;2017:6894374.
   PubMed Web of Science ®Google Scholar
• Nakayamada S, Kubo S, Yoshikawa M, Miyazaki Y, Yunoue N, Iwata S, et al. Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis. Rheumatology (Oxford) 2018;57:164–74.
   PubMed Web of Science ®Google Scholar
• Budzik GP, Colletti LM, Faltynek CR. Effects of methotrexate on nucleotide pools in normal human T cells and the CEM T cell line. Life Sci 2000;66:2297–307.
   PubMed Web of Science ®Google Scholar
• Gertel S, Polachek A, Furer V, Levartovsky D, Sidis H, Pel S, et al. T cell functions of psoriatic arthritis patients are regulated differently by TNF, IL-17A and IL-6 receptor blockades in vitro. Clin Exp Rheumatol 2022;40:120–8.
   PubMed Web of Science ®Google Scholar
• Gertel S, Polachek A, Furer V, Paran D, Tzemach R, Levartovsky D, et al. Synovial monocytes from psoriatic and rheumatoid arthritis patients are modulated differently by TNF inhibitors and glucocorticoids: an ex-vivo study. Clin Exp Rheumatol 2023;41:1847–55.
   PubMed Web of Science ®Google Scholar
• Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665–73.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569–81.
   PubMed Web of Science ®Google Scholar
• Kivity S, Zafrir Y, Loebstein R, Pauzner R, Mouallem M, Mayan H. Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients. Autoimmun Rev 2014;13:1109–13.
   PubMed Web of Science ®Google Scholar
• Siljehult F, Arlestig L, Eriksson C, Rantapaa-Dahlqvist S. Concentrations of infliximab and anti-drug antibodies in relation to clinical response in patients with rheumatoid arthritis. Scand J Rheumatol 2018;47:345–50.
   PubMed Web of Science ®Google Scholar
• Noack M, Miossec P. Effects of methotrexate alone or combined with arthritis-related biotherapies in an in vitro co-culture model with immune cells and synoviocytes. Front Immunol 2019;10:2992.
   PubMed Web of Science ®Google Scholar
• Brown PM, Pratt AG, Isaacs JD. Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol 2016;12:731–42.
   PubMed Web of Science ®Google Scholar
• Cronstein BN, Sitkovsky M. Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases. Nat Rev Rheumatol 2017;13:41–51.
   PubMed Web of Science ®Google Scholar
• Chan ES, Cronstein BN. Methotrexate–how does it really work? Nat Rev Rheumatol 2010;6:175–8.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Bisso A, Sulli A, Felli L, Briata M, Pizzorni C, et al. Antiproliferative and antiinflammatory effects of methotrexate on cultured differentiating myeloid monocytic cells (THP-1) but not on synovial macrophages from patients with rheumatoid arthritis. J Rheumatol 2000;27:2551–7.
   PubMed Web of Science ®Google Scholar
• Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum 2004;50:1370–82.
   PubMed Web of Science ®Google Scholar
• Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford) 2010;49:1215–28.
   PubMed Web of Science ®Google Scholar
• Kawanaka N, Yamamura M, Aita T, Morita Y, Okamoto A, Kawashima M, et al. CD14+,CD16+ blood monocytes and joint inflammation in rheumatoid arthritis. Arthritis Rheum 2002;46:2578–86.
   PubMedGoogle Scholar
• Paoletti A, Rohmer J, Ly B, Pascaud J, Riviere E, Seror R, et al. Monocyte/macrophage abnormalities specific to rheumatoid arthritis are linked to miR-155 and are differentially modulated by different TNF inhibitors. J Immunol 2019;203:1766–75.
   PubMed Web of Science ®Google Scholar
• Mitoma H, Horiuchi T, Hatta N, Tsukamoto H, Harashima S, Kikuchi Y, et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 2005;128:376–92.
   PubMed Web of Science ®Google Scholar
• Mitoma H, Horiuchi T, Tsukamoto H, Ueda N. Molecular mechanisms of action of anti-TNF-alpha agents - comparison among therapeutic TNF-alpha antagonists. Cytokine 2018;101:56–63.
   PubMed Web of Science ®Google Scholar
• Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008;58:1248–57.
   PubMed Web of Science ®Google Scholar
• Eer G, Kirchner S, Lindner H, Kolch W, Janosch P, Grell M, et al. Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. J Immunol 2000;164:6193–8.
   PubMed Web of Science ®Google Scholar
• Kirchner S, Boldt S, Kolch W, Haffner S, Kazak S, Janosch P, et al. LPS resistance in monocytic cells caused by reverse signaling through transmembrane TNF (mTNF) is mediated by the MAPK/ERK pathway. J Leukoc Biol 2004;75:324–31.
   PubMed Web of Science ®Google Scholar
• Meusch U, Rossol M, Baerwald C, Hauschildt S, Wagner U. Outside-to-inside signaling through transmembrane tumor necrosis factor reverses pathologic interleukin-1beta production and deficient apoptosis of rheumatoid arthritis monocytes. Arthritis Rheum 2009;60:2612–21.
   PubMedGoogle Scholar
• Suzuki M, Hashizume M, Yoshida H, Shiina M, Mihara M. IL-6 and IL-1 synergistically enhanced the production of MMPs from synovial cells by up-regulating IL-6 production and IL-1 receptor I expression. Cytokine 2010;51:178–83.
   PubMed Web of Science ®Google Scholar
• Henningsson L, Eneljung T, Jirholt P, Tengvall S, Lidberg U, van den Berg WB, et al. Disease-dependent local IL-10 production ameliorates collagen induced arthritis in mice. PLoS One 2012;7:e49731.
   PubMed Web of Science ®Google Scholar
• Wang Q, Oryoji D, Mitoma H, Kimoto Y, Koyanagi M, Yokoyama K, et al. Methotrexate enhances apoptosis of transmembrane TNF-expressing cells treated with anti-TNF agents. Front Immunol 2020;11:2042.
   PubMed Web of Science ®Google Scholar